The 100 Days Mission and What Makes a Vaccine Platform Truly Ready

Key points#

• "Ready" is not a single score. A vaccine platform is ready for a fast pandemic response only when several separate properties align at once.
• The 100 Days Mission asks for a safe, effective vaccine within 100 days of identifying a new pathogen. During COVID-19 the fastest vaccines arrived in roughly 326 days.
• Two 2025 CEPI frameworks turn "readiness" into something you can inspect: a six-dimension dashboard and a manufacturing timeline with three realistic scenarios.
• The 100-day figure only holds for a familiar pathogen with a known candidate. Less-characterized or novel pathogens push the timeline to 150 to 230 days.
• When someone says a platform is "pandemic-ready," the useful question is: ready on which dimension, and what is left unproven.

The short answer#

A vaccine platform is ready for rapid pandemic response when three things are true at the same time. It can be recoded for a new pathogen without rebuilding its manufacturing and testing processes. Its facilities and supply chains can scale that process without starting over. And regulators already understand the technology from prior use, so approval does not begin from a blank page. In 2025 the Coalition for Epidemic Preparedness Innovations (CEPI) published two frameworks that spell these properties out, which means you can now measure a readiness claim against a structured checklist instead of accepting it on the strength of confident language.

What "ready in 100 days" actually demands#

The 100 Days Mission sets a target: have a safe, effective, and accessible vaccine ready for initial authorization and large-scale manufacturing within 100 days of recognizing a new pandemic pathogen. The number is meant to provoke. By way of comparison, CEPI notes that during COVID-19 the first safe and effective vaccines were reaching people about 326 days after the viral genome became available. That was fast by any historical measure, and still more than three times the 100-day goal.

Why push for a number that has never been met? Because the counterfactual is large. CEPI's modeling suggests that if vaccines had been available roughly 100 days after the January 2020 genome release, a meaningful share of pandemic deaths might have been prevented. Those are model outputs, not measured results, so they describe the direction and rough scale of the possible benefit rather than a precise prediction. The mission has since been adopted by G7 and G20 leaders. The political endorsement matters mostly because it forced the field to write down, in advance, exactly what has to be true for a 100-day response to be physically possible at all.

Six axes, not one number#

CEPI's Platform Readiness Dashboard, published in the journal Vaccines in 2025, resists the temptation to collapse maturity into a single grade. Instead it scores a platform on six separate dimensions.

• Adaptability: how easily the platform can be modified for a new pathogen without changing its manufacturing or analytical methods.
• Compatibility: whether the platform actually fits the outbreak in question, including prior work with the relevant viral family and suitability for the target population.
• Suitability: the practical deployment factors, such as stability, safety, cost, and intellectual property clearance.
• Regulatory: how familiar authorities already are with the platform and whether it has any prior authorization history.
• Manufacturing: scalability, the ability to transfer the technology to other sites, and supply chain resilience.
• Facility readiness: good manufacturing practice (GMP) compliance and analytical testing capacity.

The dashboard covers nucleic acid platforms (RNA and DNA), protein subunit vaccines, and viral vectored vaccines, and it deliberately leaves live attenuated and inactivated approaches outside its scope. Each dimension gets a simple color grade from high to low readiness, plus a separate category for missing information. That last category is the honest part of the design. It records what is not yet known, which is precisely the detail you want and a promotional summary tends to skip.

The structural lesson is the whole point. A platform can score brilliantly on one axis and poorly on another, and a real outbreak response depends on balanced performance across all six at once. A technology that adapts to a new sequence within days but has no qualified regional manufacturing is not 100-day ready. Neither is one with abundant capacity but no regulatory track record.

Where the days actually go#

The second 2025 framework, a Chemistry, Manufacturing and Controls (CMC) rapid response framework also published in Vaccines, is valuable because it converts the abstract goal into a timeline and shows where the days are spent. It divides the work into five functional areas: drug substance and product process, formulation and stability, analytical methods, material controls and supply chain, and manufacturing facilities. Each has to be largely built in advance, during the calm between outbreaks, rather than improvised once one begins.

The framework is refreshingly candid that 100 days is only reachable in the best case, and it lays out three scenarios to prove the point.

• A familiar pathogen with a known candidate can plausibly reach conditional approval near day 100, with clinical trial material released at scale within weeks and process and analytical validation running in parallel.
• A related but less-characterized pathogen stretches the timeline to roughly 150 to 180 days, because new safety data have to come first.
• A genuinely unknown pathogen that needs fresh antigen design and preclinical work extends to roughly 200 to 230 days.

Laying these out as separate scenarios is itself a guard against overclaiming. It ties the headline number to a specific, and often optimistic, set of starting conditions.

The parts that break first#

The same framework is blunt about where responses realistically fail, and the failure points are rarely the science of the vaccine itself.

The first is manufacturing that was not arranged ahead of time. Without partnerships positioned in advance, especially in the affected regions, the hunt for a manufacturer, the scheduling, the technology transfer, and the follow-on regulatory filing all introduce delays that no amount of platform speed can claw back.

The second is regulation. Rapid conditional approval depends on agreements reached with health authorities before the outbreak, including an explicit commitment to finish the usual safety and validation work afterward. Speed at the front end is borrowed against obligations at the back end. It is not a substitute for them. A platform that looks fast on paper but has no pre-agreed regulatory path will spend its saved days waiting in a queue.

A checklist for reading a readiness claim#

Put together, the two frameworks turn a vague statement into a set of answerable questions. The next time you meet a platform described as pandemic-ready, ask:

• Ready on which dimension? Adaptability, manufacturing, and regulatory readiness are different things, and a claim may be loud on one while silent on the rest.
• Ready for which scenario? A familiar pathogen and a novel one differ by more than a hundred days.
• Is there qualified, ideally regional, manufacturing capacity, or only a process that runs in a laboratory?
• Has a regulator worked with this platform before, or would authorization start from zero?
• What has been placed in the missing-information column rather than scored as ready?

Readiness is a moving target that has to be maintained during calm stretches, when there is no outbreak to justify the spending and no headline to reward it. The value of CEPI's published dimensions is that they let funders, developers, and you tell durable preparation apart from a confident sentence. That is the distinction the next response will depend on.